Medicus Pharma Ltd. (MDCX)
NASDAQ: MDCXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MDCX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $3.16M
- EPS (TTM)
- -$76.65
- Dividend yield
- None
- 52-week range
- 1.06 – 114.00
- Day range
- 1.06 – 1.23
- Volume / Avg
- 86.72K / 116.55K
- Beta
- —
- Shares outstanding
- 2.79M
52-week range
MDCX stock today
Medicus Pharma (MDCX) closed at $1.14 on Nov 20, down 2.16% (-$0.025), versus the S&P 500's 3.70% decline. At this level, MDCX sits near the bottom of its 52-week range of $1.06 to $114.00: 99.0% below the high and 7.1% above the low. MDCX is down 25.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 46.7%.
Medicus Pharma has posted a net loss over the last twelve months (EPS of -$76.65), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Medicus Pharma
Company profileMedicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of the skin. The company has a strategic collaboration with the Gorlin Syndrome Alliance to access to SKINJECT in Patients with Gorlin Syndrome.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Raza Bokhari M.B.A., M.D.
- Headquarters
- West Conshohocken, PA
- Employees
- 16
- Website
- medicuspharma.com
Financial highlights
Full financialsMedicus Pharma reported a net loss of $47.3 million, compared with a loss of $11.2 million a year earlier. Diluted earnings per share came in at -$2.74.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | — | — | — |
| Growth | — | — | — |
| Net income | $-47.28M | $-11.16M | $-5.31M |
| EPS (diluted) | $-2.74 | $-1.16 | $-1.53 |
Analyst forecast
ForecastConsensus (4 analysts)
none
Avg. price target
$4.50+296.48%
- Strong buy 1
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 9, 2026
- EPS actual vs est.
- $-11.64 vs $-8.50
- Surprise
- -36.94%
MDCX news
All MDCX news- Medicus Regains Nasdaq Compliance Following Capital RestructuringNasdaqMDCX, HEI.A
- Medicus Pharma Regains Compliance with Nasdaq Minimum Equity Requirement for Continued ListingGlobeNewswire
- Medicus Pharma Announces Closing of $4.25 Million CEO-Led Equity Financings and $10.5 Million Debt ExchangeGlobeNewswire
- Medicus Pharma (MDCX) Q3 2026 Earnings Call TranscriptNasdaq
- Medicus Pharma to Present at BIO-Europe 2026GlobeNewswire
- Medicus Pharma Announces Proposed SkinJect® Business Combination and Concurrent FinancingGlobeNewswire
- Medicus Pharma to Present at BioFuture and Global Biotechnology SummitGlobeNewswire
- Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswire
Medicus Pharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KPRXKiora Pharmaceuticals Inc. | 0.7202 | -12.28% | $3.19M | vs MDCX |
| NRSNNeuroSense Therapeutics Ltd. | 1.28 | +1.59% | $3.19M | vs MDCX |
| AZTRAzitra Inc | 0.5168 | -2.75% | $3.13M | vs MDCX |
| GELSGelteq Limited | 0.2701 | -3.74% | $3.11M | vs MDCX |
| SKYESkye Bioscience Inc. | 0.70 | -11.03% | $3.10M | vs MDCX |
| APREAprea Therapeutics Inc. | 0.229 | -53.56% | $3.25M | vs MDCX |
| XBIOXenetic Biosciences Inc. | 1.40 | -9.09% | $3.28M | vs MDCX |
| JAGXJaguar Health Inc. | 0.227 | -30.58% | $3.03M | vs MDCX |
Indexes, lists and sector
Medicus Pharma stock FAQ
What is Medicus Pharma's stock price today?
MDCX last traded at $1.14 as of Nov 20, 4:00 PM EST, down 2.16% on the day. Prices are delayed at least 15 minutes.
Does Medicus Pharma pay a dividend?
No. Medicus Pharma does not currently pay a regular cash dividend.
Who is Medicus Pharma's CEO?
Dr. Raza Bokhari M.B.A., M.D. is the chief executive officer of Medicus Pharma Ltd., which has about 16 employees.
Has MDCX ever split its stock?
Yes. The most recent MDCX stock split was a 1-for-50 split on Oct 12, 2026.
What is the MDCX 52-week high?
The 52-week high for MDCX is $114.00 and the 52-week low is $1.06. The stock is currently 99.0% below its high.